| HS Code | 457177 |
| Iupac Name | (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione |
| Molecular Formula | C20H18FNO4 |
| Molecular Weight | 355.36 g/mol |
| Appearance | White to off-white solid |
| Solubility | Soluble in DMSO, slightly soluble in ethanol |
| Cas Number | 911045-32-6 |
| Chirality | S configuration (single stereocenter) |
| Functional Groups | Fluorophenyl, diketone, oxazolidinone, phenyl |
| Smiles | C1=CC=C(C=C1)C2COC(=O)N2CCCC(=O)C3=CC=C(F)C=C3C(=O) |
| Inchi | InChI=1S/C20H18FNO4/c21-16-10-8-15(9-11-16)19(24)7-3-6-18-22-13-14(12-26-18)17-4-1-2-5-20(17)25/h1-2,4-5,8-11,14,18H,3,6-7,12-13H2/t14-/m0/s1 |
| Boiling Point | Decomposes before boiling |
| Storage Conditions | Store at -20°C, desiccated, in tightly closed container |
| Purity | Typically >98% (HPLC) |
As an accredited (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Sealed amber glass bottle containing 5 grams of (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione, labeled with hazard and product details. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL) involves securely palletizing and packing (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione into a 20-foot container for safe transport. |
| Shipping | This chemical, **(S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione**, should be shipped in tightly sealed containers, protected from light and moisture. It must be packaged according to standard chemical safety regulations, include appropriate hazard labeling, and handled by certified carriers specializing in the transport of laboratory chemicals. Temperature-sensitive handling may be required. |
| Storage | Store (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione in a tightly sealed container, protected from light and moisture. Keep at 2–8°C (refrigerated), in a dry, well-ventilated area away from incompatible substances such as strong acids, bases, and oxidizers. Always handle under appropriate safety conditions, using gloves and eye protection, and avoid prolonged exposure to air. |
| Shelf Life | (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione is stable for 2 years when stored below 25°C, protected from light. |
As a specialist in chiral chemical synthesis, we manufacture (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione for advanced applications in value-added downstream segments. The following outlines authentic, high-value industrial applications with respective compliance, process, and product details.
Leading pharmaceutical manufacturers deploy this compound in the multi-step synthesis of advanced chiral building blocks integral to next-generation β-lactam antibiotic actives. Its stereochemical purity supports manufacturing consistency in highly regulated environments, particularly for cephalosporin and carbapenem derivatives. Operators introduce this material at the chiral induction or blocking stage, leveraging its unique moiety to configure enantioselective centers with high yield and minimal racemization.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Agrochemical producers utilize this oxazolidinone-based diketone in custom synthesis of selective herbicidal active ingredients, particularly in the creation of asymmetric centers in triketone or pyridine-type molecule frameworks. The controlled introduction of fluorinated aryl and chiral oxazolidinone units enhances bioactivity and reduces off-target toxicity, aligning with regulatory guidelines. Process chemists apply this input at the advanced intermediate stage to define precise chirality of the agrochemical actives.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
This diketone derivative finds industrial-scale adoption as a precursor in the synthesis of chiral ligands for asymmetric catalysis. Process development teams in catalyst manufacturing plants incorporate it to generate high-purity, enantiomerically enriched ligands critical for metal-catalyzed transformations. It supports batch-controlled synthesis, directly impacting catalyst selectivity and performance metrics in downstream cross-coupling and hydrogenation processes.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Peptide drug development facilities source this enantiomerically pure compound for constructing specialized peptidomimetics used in pharmaceutical research and preclinical testing. The rigid oxazolidinone ring and the fluorophenyl group contribute to chemical stability and affinity, making it a selected intermediate for side-chain introduction in bioactive peptides. Chemists introduce it during segment assembly or as a capping group for increased in vivo stability and target engagement.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8618005193850
Email: sales8@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
For decades, our team has been closely involved in the research, production, and refinement of complex small molecules used throughout advanced chemical, pharmaceutical, and agrochemical synthesis. As direct manufacturers, we don't just make chemicals from behind a desk—we work hands-on with each batch of (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione, from raw materials to final product. Our scientists oversee every synthesis and purification step, track the yields ourselves, and troubleshoot on the ground. Factory floors and fume hoods see us just as often as offices do. Years invested in oxazolidinone derivatives taught us exactly where impurities threaten yield, how moisture knocks down shelf stability, and which protocols survive real-world scale-up.
Not every molecule tells you its story plainly. With (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione, the unique chiral center—anchored by the oxazolidinone scaffold and two differentiating aryl groups—opens new doors for researchers in asymmetric synthesis. This is not a generic intermediate. The stereochemistry here—strictly (S)—comes from precise catalytic conditions that demand vigilance at every turn. Our QC specialists have spent years refining chiral separation processes to ensure that every shipment aligns with our published enantiomeric excess specifications, which consistently reach above industry-set minimums. This matters more than ever for pharmaceutical chemists whose downstream steps depend not just on purity, but on consistent optical rotation.
From the early stages of working with oxazolidinone analogues, we learned two things are non-negotiable: transparency in sourcing and complete control over the production environment. Too many operations source precursors or outsource synthesis, especially with multi-step chiral molecules, leading to quality issues or hidden impurities. In our process, every key intermediate, including the critical (S)-oxazolidinone fragment, comes out of our own reactors and passes direct analysis. Trace solvents, minor byproducts, and batch-to-batch drift—these never get swept under the rug. Instead, we've developed methods that give us reliable control over hydrolytic resistance and chemical stability, critical factors when end-users plan to store the compound over time or subject it to further synthetic manipulation.
This product is a result of iterative process improvements done first at bench scale, then pilot, before any full-scale run gets approved. Every step—condensation, fluorination, chiral resolution, crystallization—received scrutiny until the right reaction rate and isolation parameters emerged. Over time, we've also worked closely with QC teams to ensure NMR, LC, and chiral HPLC techniques capture minor peaks that lesser processes let pass. Customer feedback played a huge part here; if a batch showed minor color shifts under storage, we retested for breakdown products and tweaked workup conditions and drying profiles, keeping the end user's challenges front and center.
We realized early that customers don’t need empty technical jargon—they need specifics that speak to laboratory realities. (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione leaves our site as a white to off-white crystalline solid, a physical description that makes handling predictable and safe compared to oils or hygroscopic powders. Analytical data on each lot include NMR, LC-MS, and chiral HPLC; melting point ranges cite actual data, not historic estimates. Where applicable, our team provides spectral data on request, since clarity means fewer surprises at the bench.
Each time a customer receives this product, it comes in moisture-resistant packaging, chosen after long evaluation of chemical compatibility and practical handling. Over many batches, we've learned that even trace moisture or suboptimal sealing causes clumping or purity decline far faster than theoretical models predict. Our emphasis falls on storage conditions, not as an afterthought, but as a continuation of the molecule’s lifecycle. Vacuum-sealing protocols and nitrogen-purged containers became part of shipment not for marketing, but from repeated experience with small differences leading to major changes by the time material arrives at distant labs.
Unlike other intermediates that get by as “sufficient for most uses,” this compound plays a starring role in asymmetric transformations and intermediate building blocks. Its unique framework—a five-carbon pentanedione chain anchored with both fluoro- and phenyl-substituted termini—works as a stepping stone for enantioselective ligands, chiral auxiliaries, and several emerging antiviral and anti-infective scaffolds. In our own experience, working with researchers on the next wave of drug discovery, feedback showed that off-the-shelf analogues suffer from racemization or batch inconsistencies that waste precious time and raw material. Here, our tightly controlled (S)-enantiomeric excess, maintained consistently above 98%, makes the difference between a repeatable, trusted reaction and an uncertain one.
Our facility’s in-house analytical testing brings data-driven reliability. Laboratories ordering from us report robust performance—predictable selectivity in chiral syntheses, less variability in downstream steps, and smooth integration into scalable routes. For many laboratories refining synthetic methods, the ease by which (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione tolerates downstream functionalization and coupling reduces the bottleneck effect seen in more finicky intermediates. As a manufacturer, it’s rewarding to see our direct efforts deliver tangible savings—fewer failed batches and more successful completions.
We offer this molecule in models spanning from gram- to multi-kilogram scale, packaged for both laboratory evaluation and pilot production up through kilo-lot orders. Each size owes its existence to hard-won experience scaling novel heterocyclic chemistries without sacrificing chiral integrity. As the synthetic complexity grew, especially through the oxazolidinone ring-forming steps, we opted for vessels and agitation systems that maintained temperature and mixing at a level that supports true reproducibility—customers report minimal variation between lots, a testament to the rigor we put into scale-up engineering.
From the outset, we paid close attention to staff training and cross-functional communication on the shop floor. Each operator learns the entire batch process, because even small steps—solvent addition rate, quenching sequence, washing order—have a direct impact on yield and chirality. We treat our technical procedures as living documents, adjusting as incoming data and process experiences dictate. We never considered outsourcing any analytical controls; every run receives chiral analysis and impurity profiling on our own instruments, using solvent systems and detectors that match published literature and the latest reference patterns. Site-wide traceability builds customer trust and helps protect against the global problem of supply chain contamination—a growing concern with chiral molecules that see widespread use in early clinical development.
Comparing (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione to less rigorously-controlled variants found from trading companies or background resellers, one finds substantial differences that reach far beyond paperwork or label claims. Many brokers and third parties struggle to trace raw material quality or control the entirety of the multi-step synthesis. It’s not uncommon for customers to discover mismatched chiral purity, trace solvent residue, or non-transparent chain of custody with other sources. Our policy to synthesize every batch in-house, apply real-time analytical checks, and respond to customer feedback quickly, provides a level of support unavailable with indirect sellers who never witness the process themselves.
As chemists, we know how much the small details matter. Many of the practical bottlenecks in modern chiral synthesis—unexpected racemization, micro-impurities, slow batch turnaround—stem from cutting corners upstream. We absorb the real cost—staff training, improved analytical equipment, meticulously documented SOPs—upfront, so a customer never has to worry about whether downstream steps will run as planned. Our products move past basic specification to offer the data and transparency real laboratory workers measure in hours saved and successful syntheses, not just in paperwork or compliance.
One area where the differences become stark is in documentation and support. With each batch, our chemists share current MSDS, purity data, and, when needed, supplementary spectral and crystallographic data. We are direct points of contact for technical troubleshooting: not a call center, not a sales agent, but the hands that managed the reaction itself. Over years, this has built long-term trust with research laboratories and production chemists who need problems solved, not excuses given.
In terms of real application, (S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione fills a versatile role. Synthetic chemists use it both as a stereochemically-defined precursor for further functionalization and as a stable intermediate for chiral catalyst development. Medicinal chemists, particularly those scouting for new CNS and antiviral scaffolds, draw on its unique side-chain and oxazolidinone ring structure to deliver moieties that resist common metabolism pathways. Across medicinal projects, our partners reported more robust step-yields, particularly in Suzuki and reductive amination protocols, compared to close structural analogues. Our product’s stability profile—tightly held by real packaging and not just theoretical stability studies—reduces loss during shipping and storage, crucial for time-sensitive research programs.
Beyond pharmaceutical applications, recent developments in specialty polymer and advanced materials synthesis use our compound for stereo-specific ligand anchoring. Here as well, our ability to offer both technical support and comprehensive documentation makes us not just a supplier, but a collaborator in troubleshooting unusual reactivity or solubility issues. That commitment extends beyond the shipment; customers know they’re working with a partner who understands the process, not just the paperwork.
Direct engagement with chemists around the world has taught us never to take product reliability for granted. Increasing complexity in regulatory landscapes and sharp scrutiny on intermediate purity—especially in life sciences—means every manufacturer now faces unprecedented accountability. Over years, we prioritized full control over precursor selection, in-house small-scale and pilot production, and direct-to-laboratory shipment. No material leaves our plant unless our own team signs off on its traceability, purity, and safety support.
Supply chain disruptions, as seen over the past few years, pose a real risk to forward-planned research and discovery programs. By never outsourcing intermediary production or relying on unknown sub-suppliers, we remained resilient in the face of chemical shortages and unexpected regulatory changes. Our technical staff responds quickly to order scale-ups or process changes. We use what we learn from each new synthetic challenge—on stereoregular fluorination, advanced crystallization, or solvent tolerance—to refine SOPs and share that expertise directly with client laboratories. It’s practical, tested feedback loops, not just specification checklists, that keep our product a step ahead.
Our team members—trained as process chemists, analytical specialists, and plant engineers—approach every batch with a straightforward mindset: the utility and reliability of our product must stand up to the same conditions and scrutiny our users’ laboratories experience. Where other channels pass on problems or point fingers, we step in to solve process or technical questions ourselves. Experience has shown that no amount of sales polish can cover a compound that fails real-world chiral control or leaves unexplained residue after workup. Trust in our production process means more researchers see consistent success, a claim built on years of honest feedback, failed runs, and continuous effort.
Each new run gives us another opportunity to refine, learn, and improve—not for a PowerPoint slide, but for the actual advancement of industrial and academic chemistry. Our open-door policy for process tours and data sharing ensures anyone interested in tracing our quality commitment can see with their own eyes what it takes to make a specialized compound right.
This product—(S)-1-(4-fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione—doesn’t just represent another chiral intermediate in a catalogue. Each gram reflects improvements in process control, quality systems, and hands-on expertise. We know researchers expect more than commodity chemicals; they require a steady stream of reproducible, transparent, and technically supported materials to pioneer new frontiers. Community trust in our molecules comes from transparency, dedication, and the simple fact that we’re not just suppliers—we’re the chemists making the difference behind every bottle.